How do elevated triglycerides and low HDL-cholesterol affect inflammation and atherothrombosis?

Current Cardiology Reports

Volumn 15, Issue 9, 2013, Pages

  Welty, Francine K ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Apolipoprotein C III; Apolipoproteins; Cholesterol efflux; Fatty streak; Foam cells; HDL C; Inflammation; Insulin resistance; Metabolic syndrome; Reverse cholesterol transport; Toll receptors; Triglyceride; Triglyceride rich lipoproteins

Indexed keywords

APOLIPOPROTEIN C3; BEZAFIBRATE; CHOLESTEROL ABSORPTION INHIBITOR; EVOLOCUMAB; EZETIMIBE; FATTY ACID; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; SIMVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; AUTACOID; BIOLOGICAL MARKER;

ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CORONARY ARTERY DISEASE; EXERCISE; HEART PROTECTION; HUMAN; HYPERTRIGLYCERIDEMIA; IMMUNOREGULATION; INFLAMMATION; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIPID COMPOSITION; MEDICAL RESEARCH; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PREDICTION; REVIEW; THROMBOSIS; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION; ATHEROSCLEROTIC PLAQUE; BLOOD; PHYSIOLOGY;

ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CHOLESTEROL, HDL; CORONARY ARTERY DISEASE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; METABOLIC SYNDROME X; PLAQUE, ATHEROSCLEROTIC; THROMBOSIS; TRIGLYCERIDES;

EID: 84885121128     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-013-0400-4     Document Type: Review

References (111)

1. Barter P, Gotto AM, LaRosa JC, et al. Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol and cardiovascular events. N Engl J Med. 2007;357:1301-10. (Pubitemid 47481452)
2. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640-5.
3. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA. 2002;287:356-9. (Pubitemid 34251969)
4. Welty FK. The Contribution of Triglycerides and Triglyceride-Rich Lipoproteins to Atherosclerotic Cardiovascular Disease. In: Blumenthal RG, editor. Preventive Cardiology, a Companion to Braunwald's Heart Disease. Philadelphia: Elsevier Saunders; 2011. p. 230-51.
5. Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2007;115:450-8. (Pubitemid 46184196)
6. Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302:1993-2000.
7. Brunner D, Altman S, Loebl K, Schwartz S, Levin S. Serum cholesterol and triglycerides in patients suffering from ischemic heart disease and in healthy subjects. Atherosclerosis. 1977;28:197-204. (Pubitemid 8213765)
8. Wilhelmsen L, Bengtsson C, Elmfeldt D, et al. Multiple risk prediction of myocardial infarction in women as compared with men. Br Heart J. 1977;39:1179-85. (Pubitemid 8206508)
9. Scott DW, Gotto AM, Cole JS, Gorry GA. Plasma lipids as collateral risk factors in coronary artery disease: a study of 371 males with chest pain. J Chronic Dis. 1978;31:337-45. (Pubitemid 9024755)
10. Gotto AM, Gorry GA, Thompson JR, et al. Relationship between plasma lipid concentrations and coronary artery disease in 496 patients. Circulation. 1977;56:875-83. (Pubitemid 8235199)
11. Anderson AJ, Barboriak JJ, Rimm AA. Risk factors and angiographically determined coronary occlusion. Am J Epidemiol. 1978;107:8-14. (Pubitemid 8308178)
12. Cabin HS, Roberts WC. Relation of serum total cholesterol and triglyceride levels to the amount and extent of coronary arterial narrowing by atherosclerotic plaque in coronary heart disease: quantitative analysis of 2,037 five mm segments of 160 major epicardial coronary arteries in 40 necropsy patients. Am J Med. 1982;73:227-34. (Pubitemid 13203920)
13. Reardon MF, Nestel PJ, Craig IH, Harper RW. Lipoprotein predictors of the severity of coronary artery disease in men and women. Circulation. 1985;71:881-8. (Pubitemid 15035237)
14. Freedman DS, Gruchow HW, Anderson AJ, Rimm AA, Barboriak JJ. Relation of triglyceride levels to coronary artery disease: the Milwaukee Cardiovascular Data Registry. Am J Epidemiol. 1988;127:1118-30.
15. Castelli WP, Doyle JT, Gordon T, et al. HDL cholesterol and other lipids in coronary heart disease: the Cooperative Lipoprotein Phenotyping Study. Circulation. 1977;55:767-72. (Pubitemid 8090093)
16. Fager G, Wiklund O, Olofsson SO, Wilhelmsen L, Bondjers G. Multivariate analyses of serum apolipoproteins and risk factors in relation to acute myocardial infarction. Arteriosclerosis. 1981;1:273-9. (Pubitemid 12229735)
17. Kukita H, Imamura Y, Hamada M, Joh T, Kokubu T. Plasma lipids and lipoproteins in Japanese male patients with coronary artery disease and in their relatives. Atherosclerosis. 1982;42:21-9. (Pubitemid 12172126)
18. Hamsten A, Walldius G, Dahlén G, Johansson B, De Faire U. Serum lipoproteins and apolipoproteins in young male survivors of myocardial infarction. Atherosclerosis. 1986;59:223-35. (Pubitemid 16170433)
19. •• Miller M, Stone NJ, Ballantyne C, on behalf of the American Heart Association Clinical Lipidology, Thrombosis, and Prevention Committee of the Council on Nutrition, Physical Activity and Metabolism, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiovascular Nursing, and Council on the Kidney in Cardiovascular Disease, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011;123:2292-333. This AHA statement summarizes evidence supporting the role of triglycerides in cardiovascular risk and provides recommendations for management.
20. Ginsberg HN. New perspectives on atherogenesis: role of abnormal triglyceride-rich lipoprotein metabolism. Circulation. 2002;106:2137-42. (Pubitemid 35192822)
21. Havel RJ, Kane JP. Introduction: structure and metabolism of plasma lipoproteins. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The Metabolic and Molecular Bases of Inherited Disease. 7th ed. New York: McGraw-Hill; 1995. p. 1841-51.
22. Young SG. Recent progress in understanding apolipoprotein B. Circulation. 1990;82(5):1574-94. (Pubitemid 20367961)
23. Chen SH, Habib G, Yang CY, et al. Apolipoprotein B-48 is the product of a messenger RNA with an organ-specific in-frame stop codon. Science. 1987;238(4825):363-6. (Pubitemid 17151728)
24. Berriot-Varoqueaux N, Aggerbeck LP, Samson-Bouma M, et al. The role of the microsomal triglyceride transfer protein in abetalipoproteinemia. Annu Rev Nutr. 2000;20:663-97.
25. Weisgraber KH, Rall Jr SC. Human apolipoprotein B-100 heparin-binding sites. J Biol Chem. 1987;262(23):11097-103. (Pubitemid 17122864)
26. Sehayek E, Lewin-Velvert U, Chajek-Shaul T, Eisenberg S. Lipolysis exposes unreactive endogenous apolipoprotein E-3 in human and rat plasma very low density lipoprotein. J Clin Invest. 1991;88(2):553-60.
27. Beigneux AP, Davies BS, Gin P, Weinstein MM, et al. Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 plays a critical role in the lipolytic processing of chylomicrons. Cell Metab. 2007;5(4):279-91. (Pubitemid 46477852)
28. Kowal RC, Herz J, Goldstein L, et al. Low density lipoprotein receptor-related protein mediates uptake of cholesteryl esters derived from apoprotein E-enriched lipoproteins. Proc Natl Acad Sci USA. 1989;86(15):5810-4. (Pubitemid 19217543)
29. Mahley RW, Hussain M. Chylomicron and chylomicron remnant catabolism. Curr Opin Lipidol. 1991;2:170-6.
30. Welty FK, Lichtenstein AH, Barrett PHR. Human apolipoprotein (Apo) B-48 and ApoB-100 kinetics with stable isotopes. Arterioscler Thromb Vasc Biol. 1999;19(12):2966-74. (Pubitemid 30029826)
31. Ooi EM, Barrett PH, Chan DC, Watts GF. Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. Clin Sci (Lond). 2008;114:611-24. (Pubitemid 351589061)
32. Zheng C, Khoo C, Furtado J, Sacks FM. Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype. Circulation. 2010;121:1722-34.
33. Rapp RJ. Hypertriglyceridemia: a review beyond low-density lipoprotein. Cardiol Rev. 2002;10:163-72. (Pubitemid 34746800)
34. Pollin TI, Damcott CM, Shen H, et al. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science. 2008;322:1702-5.
35. Kawakami A, Osaka M, Aikawa M, et al. Toll-like receptor 2 mediates apolipoprotein CIII-induced monocyte activation. Circ Res. 2008;103:1402-9.
36. Kawakami A, Aikawa M, Libby P, et al. Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells. Circulation. 2006;113:691-700.
37. Kawakami A, Aikawa M, Alcaide P, et al. Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells. Circulation. 2006;114:681-7. (Pubitemid 44252310)
38. Lee SJ, Campos H, Moye LA, Sacks FM. LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients. Arterioscler Thromb Vasc Biol. 2003;23:853-8. (Pubitemid 36566177)
39. •• Petersen KF, Dufour S, Hariri A, et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med. 2010;362:1082-9. Important research providing insight into role of ApoCIII gene variants in pathophysiology of nonalcoholic fatty liver disease.
40. Tsai MY, Ordovas JM. APOC3 mutation, serum triglyceride concentrations, and coronary heart disease. Clin Chem. 2009;55:1274-6.
41. Guilherme A, Virbasius JV, Puri V, Czech MP. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol. 2008;9:367-77. (Pubitemid 351574198)
42. • Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011;11:98-107. Excellent review of inflammatory mechanisms and signaling underlying Type 2 diabetes.
43. Pavlic M, Valero R, Duez H, et al. Triglyceride-rich lipoprotein- associated apolipoprotein C-III production is stimulated by plasma free fatty acids in humans. Arterioscler Thromb Vasc Biol. 2008;28:1660-5.
44. Fabbrini E, Mohammed BS, Magkos F, et al. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology. 2008;134:424-31. (Pubitemid 351173050)
45. Sparks JD, Sparks CE. Insulin modulation of hepatic synthesis and secretion of apolipoprotein B by rat hepatocytes. J Biol Chem. 1990;265:8854-62.
46. Ginsberg HN, Fisher EA. The ever-expanding role of degradation in the regulation of apolipoprotein B metabolism. J Lipid Res. 2009;50(suppl):S162-6.
47. Sato R, Miyamoto W, Inoue J, et al. Sterol regulatory element-binding protein negatively regulates microsomal triglyceride transfer protein gene transcription. J Biol Chem. 1999;274:24714-20. (Pubitemid 29404671)
48. •• Eckel RH. The Complex Metabolic Mechanisms Relating Obesity to Hypertriglyceridemia. Arterioscler Thromb Vasc Biol. 2011;31:1946-8. Comprehensive review summarizing relation between obesity, insulin resistance and hypertriglyceridemia.
49. •• Goldberg IJ, Eckel RH, McPherson R. Triglycerides and heart disease: Still a hypothesis? Arterioscler Thromb Vasc Biol. 2011;31:1716-25. Outstanding review of triglyceride metabolism and relation to cardiovascular disease with update on genetics and clinical trials of triglyceride-lowering therapies.
50. • Rask-Madsen C, Kahn CR. Tissue-specific insulin signaling, metabolic syndrome and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2012;32:2052-9. Review summarizing known mechanisms of insulin signaling on various organ systems.
51. Hurt-Camejo E, Olsson U, Wiklund O, et al. Cellular consequences of the association of apoB lipoproteins with proteoglycans. Potential contribution to atherogenesis. Arterioscler Thromb Vasc Biol. 1997;17:1011.
52. Napoli C, D'Armiento FP, Mancini FP. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J Clin Invest. 1997;100:2680-90. (Pubitemid 28007535)
53. • Fang L, Green SR, Baek JS, et al. In vivo visualization and attenuation of oxidized lipid accumulation in hypercholesterolemic zebrafish. J Clin Invest. 2011;121:4861-9. Very interesting research showing that cholesterol feeding of zebrafish larvae leads to oxidized lipid accumulation, a finding suggesting that diet-induced inflammation is wide-spread in nature.
54. Podrez EA, Febbraio M, Sheibani N, et al. Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species. J Clin Invest. 2000;105:1095.
55. Zilversmith DB. A proposal linking atherogenesis to the interaction of endothelial lipoprotein lipase with triglyceride-rich lipoproteins. Circ Res. 1973;33:633-8.
56. Mamo JC, Proctor SD, Smith D. Retention of chylomicron remnants by arterial tissue; importance of an efficient clearance mechanism from plasma. Atherosclerosis. 1998;141 suppl 1:S63-9.
57. Varbo A, Benn M, Tybjaerg-Hansen A, et al. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2013;61:427-36.
58. Kugiyama K, Doi H, Motoyama T, et al. Association of remnant lipoprotein levels with impairment of endothelium-dependent vasomotor function in human coronary arteries. Circulation. 1998;97:2519.
59. Krauss RM, Lindgren FT, Williams PT, et al. Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolaemic men. Lancet. 1987;2:62.
60. Kugiyama K, Dori H, Takazoe K, et al. Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. Circulation. 1999;99:2858.
61. Fukushima H, Kugiyama K, Sugiyama S, et al. Comparison of remnant-like lipoprotein particles in postmenopausal women with and without coronary artery disease and in men with coronary artery disease. Am J Cardiol. 2001;88:1370. (Pubitemid 34008679)
62. Masuoka H, Kamei S, Wagayama H, et al. Association of remnant-like particle cholesterol with coronary artery disease in patients with normal total cholesterol levels. Am Heart J. 2000;139:305.
63. Williams KJ, Petrie KA, Broacia RW, Swenson TL. Lipoprotein lipase modulates net secretory output of apolipoprotein B in vitro. J Clin Invest. 1991;88:1300.
64. Hodis HN, Mack WJ, Dunn M, et al. Intermediate-density lipoproteins and progression of carotid arterial wall intima-media thickness. Circulation. 2022;1997:95.
65. Hodis HN, Mack WJ. Triglyceride-rich lipoproteins and the progression of coronary artery disease. Curr Opin Lipidol. 1995;6:209.
66. Mack WJ, Krauss RM, Hodis HN. Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS). Treatment effects and relation to coronary angiographic progression. Arterioscler Thromb Vasc Biol. 1996;16:697.
67. Tsuda T, Yoshimura H, Hamasaki N. Effect of phosphatidylcholine, phosphatidylethanolamine and lysophosphatidylcholine on the activated factor X-prothrombin system. Blood Coagul Fibrinolysis. 2006;17:465-9. (Pubitemid 44231692)
68. Eriksson P, Nilsson L, Karpe F, Hamsten A. Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia. Arterioscler Thromb Vasc Biol. 1998;18:20-6. (Pubitemid 28047594)
69. Han S, Liang CP, DeVries-Seimon T, et al. Macrophage insulin receptor defi-ciency increases ER stress-induced apoptosis and necrotic core formation in advanced atherosclerotic lesions. Cell Metab. 2006;3:257-66.
70. •• Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell. 2011;145:341-55. This is an excellent review of mechanisms by which macrophages lead to acute coronary sydromes.
71. Nishi K, Itabe H, Uno M, et al. Oxidized LDL in carotid plaques and plasma associates with plaque instability. Arterioscler Thromb Vasc Biol. 2002;22:1649-54.
72. Yancey PG, Bortnick AE, Kellner-Weibel G, et al. Importance of different pathways of cellular cholesterol efflux. Arterioscler Thromb Vasc Biol. 2003;23:712-9. (Pubitemid 36566157)
73. • Francis GA. The complexity of HDL. Biochim Biophys Acta. 2010;1801:1286-93. Comprehensive overview of HDL composition and function.
74. Acton S, Rigotti A, Landschulz KT, et al. Identification of scavenger receptor SR-BI as a high-density lipoprotein receptor. Science. 1996;271:518-20.
75. Steinberg D. A docking receptor for HDL cholesterol esters. Science. 1996;271:460-1. (Pubitemid 26044461)
76. Lamarche B, Uffelman KD, Carpentier A, et al. Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men. J Clin Invest. 1999;103(8):1191-9. (Pubitemid 29207253)
77. Nigon F, Lesnik P, Rouis M, et al. Discrete subspecies of human low density lipoprotein are heterogeneous in their interaction with cellular LDL receptor. J Lipid Res. 1991;32:1741.
78. Swenson TL. The role of the cholesteryl ester transfer protein in lipoprotein metabolism. Diabetes Metab Rev. 1991;7:139-53.
79. Brinton EA, Eisenberg S, Breslow JL. Human HDL cholesterol levels are determined by apoA-I fractional catabolic rate, which correlates inversely with estimates of HDL particle size. Effects of gender, hepatic and lipoprotein lipases, triglyceride and insulin. Arterioscler Thromb. 1994;14(5):707-20.
80. Duffy D, Rader DJ. Update on strategies to increase HDL quantity and function. Nat Rev Cardiol. 2009;6:455-63.
81. •• Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364:127-35. First report showing that role of HDL in reverse cholesterol transport is more important predictor of CAD than level of HDL-C; thus, suggesting that functionality of HDL may be more important than HDL-C level.
82. •• Posadas-Sanchez R, Posadas-Romero C, Mendoza-Perez E, et al. Cholestrol efflux and metabolic abnormalities associated with low high-density-lipoprotein-cholesterol and high triglycerides in statin-treated coronary men with low-density lipoprotein-cholestrol < 70 mg/dL. Am J Cardiol. 2012;109:636-41. First report to show that decreased cholesterol efflux may account for residual risk observed in statin-treated patients with high triglycerde level and low HDL-C level.
83. •• Fisher EA, Feig JE, Hewing B, et al. High-density lipoprotein function, dysfunction, and reverse cholesterol transport. Arterioscler Thromb Vasc Biol. 2012;32:2813-20. Outstanding review of beneficial, cardioprotective effects of HDL including animal models, in vitro and clinical trials.
84. • Owen DM, Magenau A, Williamson D, Gaus K. The lipid raft hypothesis revisited - New insights on raft composition and function from super-resolution fluorescence microscopy. Bioessays. 2012;34:739-47. Provides summary of lipid raft composition and function.
85. Haraba R, Antohe F. T cells are active participants in the progression of atherosclerotic plaques. Dig J Nanomater Bios. 2011;6:1529-34.
86. Taleb S, Tedgui A, Mallat Z. Adaptive T cell immune responses and atherogenesis. Curr Opin Pharmacol. 2010;10:197-202.
87. Lichtman AH. T cell costimulatory and coinhibitory pathways in vascular inflammatory diseases. Front Physiol. 2012;3:18.
88. Lahoute C, Herbin O, Mallat Z, Tedgui A. Adaptive immunity in atherosclerosis: mechanisms and future therapeutic targets. Nat Rev Cardiol. 2011;8:348-58.
89. Foks AC, Frodermann V, ter Borg M, et al. Differential effects of regulatory T cells on the initiation and regression of atherosclerosis. Atherosclerosis. 2011;218:53-60.
90. Ait-Oufella H, Salomon BL, Potteaux S, et al. Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med. 2006;12:178-80. (Pubitemid 43214743)
91. Maganto-García E, Tarrio ML, Grabie N, Bu DX, Lichtman AH. Dynamic changes in regulatory T cells are linked to levels of diet-induced hypercholesterolemia. Circulation. 2011;124:185-95.
92. Wilhelm AJ, Zabalawi M, Owen JS, et al. Apolipoprotein A-I modulates regulatory T cells in autoimmune LDLr-/-, ApoA-I-/- mice. J Biol Chem. 2010;285:36158-69.
93. Wilhelm AJ, Zabalawi M, Grayson JM, et al. Apolipoprotein A-I and its role in lymphocyte cholesterol homeostasis and autoimmunity. Arterioscler Thromb Vasc Biol. 2009;29:843-9.
94. Dong L, Watanabe K, Itoh M, et al. CD4+ T-cell dysfunctions through the impaired lipid rafts ameliorate concanavalin A-induced hepatitis in sphingomyelin synthase 1-knockout mice. Int Immunol. 2012;24:327-37.
95. Yin K, Chen WJ, Zhou ZG, et al. Apolipoprotein A-I inhibits CD40 proinflammatory signaling via ATP-binding cassette transporter A1-mediated modulation of lipid raft in macrophages. J Atheroscler Thromb. 2012;19:823-36.
96. •• Cheng AM, Handa P, Tateya S, et al. Apolipoprotein A-I attenuates palmitate-mediated NF-KB activation by reducing Toll-like receptor-4 recruitment into lipid rafts. PLoS One. 2012;7:e33917. Excellent research showing how ApoA-I reduces inflammation via TLR4 receptor induced by the fatty acid palmitate.
97. •• Sorci-Thomas MG, Thomas MJ. High density lipoprotein biogenesis, cholesterol efflux and immune cell function. Arterioscler Thromb Vasc Biol. 2012;32:2561-5. Excellent review of role of HDL in cholesterol efflux and regulation of T cell function to reduce atherosclerosis.
98. •• Navab M, Reddy ST, Van Lenten BJ, et al. High-density lipoprotein and 4F peptide reduce systemic inflammation by modulating intestinal oxidized lipid metabolism: Novel hypotheses and review of literature. Arterioscler Thromb Vasc Biol. 2012;32:2553-60. Informative review of cardioprotective and anti-inflammatory effects of HDL with emphasis on antioxidative properties.
99. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Circulation. 2002;106:3143-421.
100. Abate N, Vega GL, Grundy SM. Variability in cholesterol content and physical properties of lipoproteins containing apolipoprotein B-100. Atherosclerosis. 1993;104:159-71. (Pubitemid 24035644)
101. •• Reiner Z, Catapan AL, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2011;32:1769-818. Outstanding summary of the clinical trial evidence supporting scoring for risk factor assessment and recommendations for evaluation and management of dyslipidaemias.
102. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation. 1990;82:495-506. (Pubitemid 20257828)
103. Shaw K, Gennat H, O'Rourke P, Del Mar C. Exercise for overweight or obesity. Cochrane Database Syst Rev. 2006, 4CD003817.
104. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317(20):1237-45. (Pubitemid 17147964)
105. Scott R, O'Brien R, Fulcher G, on behalf of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators, et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome. Diabetes Care. 2009;32:493-8.
106. Rubins HB, Robins SJ, Collins D, Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 1999;341(6):410-8. (Pubitemid 29362514)
107. The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary heart disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000, 102: 21- 27.
108. ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563-74.
109. AIM-HIGH Investigators, Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255-67.
110. http://www.theheart.org/article accessed 2/3/2013.
111. Koren MJ, Scott R, Kim JB, et al. Efficacy, safety and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomized, double-blind, placebo-controlled, phase 2 study. Lancet. 2012;380:1995-2006.